Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
NCT00783341
Last updated date
ABOUT THIS STUDY
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending
doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Healthy Subjects
Sex
Females and Males
Age
18-50 years
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Healthy SubjectsPhase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
NCT02034591
- San Antonio, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Healthy SubjectsTHE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC
NCT02625207
- New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Healthy SubjectsA Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
NCT01250756
- Isumi-city, Chiba
- Matsuyama-city, Ehime
- Itoshima, Fukuoka
- Kasuga, Fukuoka
- Sapporo-city, Hokkaido
- Sapporo, Hokkaido
- Sapporo, Hokkaido
- Sapporo, Hokkaido
- Kuwana, Mie
- Kurashiki, Okayama
- Okayama-city, Okayama
- Toyonaka, Osaka
- Kumagaya-city, Saitama
- Chiba,
- Fukuoka,
- Fukuoka,
- Fukuoka,
- Fukuoka,
ALL GENDERS
3 Months+
years
MULTIPLE SITES
Healthy SubjectsTrial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
NCT01200368
- Funabashi, Chiba
- Isumi-city, Chiba
- Matsuyama-city, Ehime
- Higashi-ku, Fukuoka-city, Fukuoka
- Fukuyama, Hiroshima
- Kure, Hiroshima
- Sapporo, Hokkaido
- Sapporo, Hokkaido
- Sapporo, Hokkaido
- Sapporo, Hokkaido
- Sapporo, Hokkaido
- Kikuchi-gun, Kumamoto
- Suzuka, MIE
- Tsu, MIE
- Tsu, MIE
- Kumagaya-city, Saitama
- Kumagaya, Saitama
- Fuchu, Tokyo
- Ota-ku, Tokyo
- Setagaya-ku, Tokyo
- Setagaya-ku, Tokyo
- Tachikawa-shi, Tokyo
- Tama, Tokyo
- Kofu, Yamanashi
- Koushu-shi, Yamanashi
- Tsuru-shi, Yamanashi
- Fukuoka,
- Fukuoka,
- Kumamoto,
- Kumamoto,
- Kumamoto,
- Okayama,
ALL GENDERS
3 Months+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously | |||
Official Title ICMJE | An Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as 6-Day Continuous Infusions to Healthy Subjects | |||
Brief Summary | This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Double Primary Purpose: Treatment | |||
Condition ICMJE | Healthy Subjects | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 25 | |||
Original Estimated Enrollment ICMJE | 24 | |||
Actual Study Completion Date ICMJE | February 2009 | |||
Actual Primary Completion Date | February 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion
Exclusion
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 50 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00783341 | |||
Other Study ID Numbers ICMJE | 3205K2-1001 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth | |||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Verification Date | July 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |